Connect with us

Hi, what are you looking for?

News

NAFDAC Disagrees With WHO on Chloroquine Clinical Trials

Notwithstanding the decision of the World Health Organisation (WHO) to suspend clinical trials of Hydroxychloroquine and Chloroquine for the treatment of COVID-19, the National Agency for Food and Drug Administration and Control (NAFDAC) will continue the experiment in Nigeria, the agency’s Director-General, Prof. Mojisola Adeyeye, has said.

She said yesterday on a Lagos-based private broadcast station, TVC, programme, that there were proven records that Hydroxychloroquine had been effective in the treatment of COVID-19 patients, especially those at the “mild stage” of the virus.

The virus infected 276 more Nigerians yesterday, bringing the total infections to 8,344 with 2,385 persons discharged and 249 deaths spread across 34 states and the Federal Capital Territory.

The Nigeria Centre for Disease Control (NCDC) reported last night that the new cases were reported from 15 states, including Lagos 161, Rivers 36, Edo 27, Kaduna 19, Nasarawa 10, Oyo six, Kano four, Delta three, and Ebonyi, three.

Gombe, Ogun, Ondo, Borno, Abia and Bauchi had one each.

However, as the pandemic continues to ravage the world, former President Goodluck Jonathan has asked African countries to look inward for remedies.

WHO on Monday announced the temporary suspension of the clinical trials of Hydroxychloroquine as a potential drug for the treatment of COVID-19.

It said the decision followed a study that using the drug on patients could increase their chance of dying.

“The Executive Group has implemented a temporary pause of the Hydroxychloroquine arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board,” Director-General of WHO, Dr. Tedros Ghebreyesus, had said.

He stressed that Hydroxychloroquine and Chloroquine “are accepted as generally safe for use in patients with autoimmune diseases or malaria,” noting that the suspension was a temporary measure.

But Adeyeye disagreed with the WHO’s position, saying: “There is data to prove that Hydroxychloroquine worked for many COVID-19 patients. Therefore, we would continue our own clinical trials in Nigeria. Hydroxychloroquine has been proved to work at a mild stage.

“So the potency depends on the severity of the disease in the patient’s body.”

According to her, Lagos State has already begun Hydroxychloroquine clinical trials and depending on the speed of work, the clinical trials should be concluded within four months.

“If medical doctors, research scientists, pharmacists, herbal experts work together, we should conclude the clinical trial in three to four months. The narrative might change afterwards but for now, we believe in Hydroxychloroquine,” she stated.

_____

Follow us on Twitter at @thesignalng

Copyright 2020 SIGNAL. Permission to use portions of this article is granted provided appropriate credits are given to www.signalng.com and other relevant sources. 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Advertisement

Related

News

Bread producers under the auspices of the Premium Breadmakers Association of Nigeria (PBAN) have said they will be withdrawing their services in protest of...

News

The World Health Organisation (WHO) has for the first time in a while indicated that the pandemic could come to an ‘end’ in Europe...

Africa

The surge of COVID-19 driven by the Omicron variant in Africa is flattening, the World Health Organization said Thursday. As of January 11th, there...

News

Director-General of the National Agency for Food and Drug Administration and Control (NAFDAC), Prof. Mojisola Adeyeye, yesterday, stated that her organisation was working with...

Copyright ©